Clover Biopharmaceuticals, Ltd.

SEHK:2197 Stock Report

Market Cap: HK$290.5m

Clover Biopharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 2197?
Owner TypeNumber of SharesOwnership Percentage
Employee Share Scheme62,518,1314.82%
Private Companies71,870,1115.54%
Institutions116,241,1468.96%
VC/PE Firms157,593,42912.2%
Individual Insiders261,663,81120.2%
General Public627,171,30148.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 18 shareholders own 51.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.2%
Peng Liang
209,871,665HK$47.0m0.04%no data
12.2%
Hillhouse Investment Management, Ltd.
157,593,429HK$35.3m0%0.04%
5.4%
Chengdu Tianhe Conventional Chinese and Medicine Technology Nurture Co. Ltd
69,999,500HK$15.7m0%no data
4.82%
Super Novel International Limited
62,518,131HK$14.0m0%no data
3.79%
National Council for Social Security Fund
49,213,878HK$11.0m0%no data
2.71%
Lapam Capital
35,152,768HK$7.9m0%0.64%
2.36%
Chengdu Ronghui Datong Equity Investment Fund Management Co., Ltd.
30,660,000HK$6.9m0%no data
2.19%
Xiaodong Wang
28,404,875HK$6.4m0.37%no data
1.6%
Joshua G. Liang
20,734,895HK$4.6m0.59%no data
0.14%
The Core Trust Company Limited
1,870,611HK$419.0k0%no data
0.093%
GF Fund Management Co., Ltd.
1,209,500HK$270.9k0%no data
0.065%
Ralf Leo Clemens
840,608HK$188.3k6.59%no data
0.031%
Jeffrey S. Farrow
404,875HK$90.7k34.6%no data
0.031%
Thomas Edward Leggett
404,875HK$90.7k34.6%no data
0.031%
Xiaobin Wu
404,875HK$90.7k34.6%no data
0.031%
Xiang Liao
404,875HK$90.7k34.6%no data
0.015%
Donna Marie Ambrosino
192,268HK$43.1k4.22%no data
0.00039%
China Universal Asset Management Company Ltd.
5,000HK$1.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 07:01
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clover Biopharmaceuticals, Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCredit Suisse
Yang HuangCredit Suisse
Ziyi ChenGoldman Sachs